Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective hoisted by stock analysts at Mizuho from $144.00 to $150.00 in a research report issued on Tuesday, MarketBeat reports. The brokerage currently has a “neutral” rating on the specialty pharmaceutical company’s stock. Mizuho’s price objective would suggest a potential upside of 9.84% from the company’s current price.

Several other equities analysts have also recently issued reports on the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Sunday. Zacks Investment Research cut Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 10th. HC Wainwright restated a “neutral” rating and set a $150.00 target price (up previously from $144.00) on shares of Jazz Pharmaceuticals in a report on Friday, November 10th. UBS reduced their target price on Jazz Pharmaceuticals from $172.00 to $168.00 and set a “buy” rating on the stock in a report on Wednesday, November 8th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $172.00 target price (down previously from $177.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have assigned a buy rating to the company. Jazz Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $180.25.

Jazz Pharmaceuticals (NASDAQ JAZZ) traded down $1.63 during trading on Tuesday, reaching $136.56. The company had a trading volume of 273,900 shares, compared to its average volume of 509,231. The company has a market capitalization of $8,284.56, a PE ratio of 17.34, a price-to-earnings-growth ratio of 0.89 and a beta of 0.98. Jazz Pharmaceuticals has a fifty-two week low of $99.28 and a fifty-two week high of $163.75. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10.

In other news, Director Patrick G. Enright sold 352 shares of the firm’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $133.19, for a total transaction of $46,882.88. Following the sale, the director now owns 1,365 shares of the company’s stock, valued at $181,804.35. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Iain Mcgill sold 8,000 shares of the firm’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $133.42, for a total value of $1,067,360.00. Following the sale, the senior vice president now directly owns 28,383 shares in the company, valued at approximately $3,786,859.86. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,352 shares of company stock worth $1,417,763. 4.30% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its position in Jazz Pharmaceuticals by 11,990.7% in the 2nd quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after buying an additional 866,691 shares during the last quarter. FMR LLC raised its position in Jazz Pharmaceuticals by 11.4% in the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after buying an additional 849,348 shares during the last quarter. JPMorgan Chase & Co. raised its position in Jazz Pharmaceuticals by 41.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after buying an additional 410,031 shares during the last quarter. Schroder Investment Management Group acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $52,571,000. Finally, American Century Companies Inc. raised its position in Jazz Pharmaceuticals by 133.2% in the 2nd quarter. American Century Companies Inc. now owns 549,900 shares of the specialty pharmaceutical company’s stock valued at $85,509,000 after buying an additional 314,094 shares during the last quarter. 91.30% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/05/mizuho-boosts-jazz-pharmaceuticals-jazz-price-target-to-150-00.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.